Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kami J Maddocks

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
Blood Advances|August 14, 2025
Camidanlumab Tesirine for Relapsed or Refractory Classic Hodgkin Lymphoma: A Phase 2 StudyAlex F Herrera, Stephen M Ansell, Pier Luigi Zinzani, et al.
Transplantation and Cellular Therapy|August 28, 2021
American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell LymphomaPashna N Munshi, Mehdi Hamadani, Ambuj Kumar, et al.
Cancer|October 1, 2019
Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failureEmily C Ayers, Shaoying Li, L Jeffrey Medeiros, et al.
Blood Advances|August 5, 2025
Treatment and outcomes of progression of disease post-CAR T-cell therapy in mantle cell lymphoma: a multicenter analysisZachary D Epstein-Peterson, Anath Christopher Lionel, Ashlee Joseph, et al.
Blood Advances|March 12, 2021
Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphomaReid W Merryman, Robert A Redd, Taiga Nishihori, et al.
Blood Advances|October 24, 2023
Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphomaJames N Gerson, Elizabeth Handorf, Diego Villa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 8, 2019
Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab EraJames N Gerson, Elizabeth Handorf, Diego Villa, et al.
Blood Advances|February 24, 2026
Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphomaYucai Wang, Melissa C Larson, Steven R Hwang, et al.
Blood Advances|December 11, 2025
Benefit of Rituximab Maintenance After First-line Bendamustine-Rituximab in Patients with Mantle Cell LymphomaYucai Wang, Melissa C Larson, Steven R Hwang, et al.
Blood Cancer Journal|April 25, 2026
Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapyYucai Wang, Melissa C Larson, Steven R Hwang, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Blood Advances|August 14, 2025
Camidanlumab Tesirine for Relapsed or Refractory Classic Hodgkin Lymphoma: A Phase 2 StudyAlex F Herrera, Stephen M Ansell, Pier Luigi Zinzani, et al.
Transplantation and Cellular Therapy|August 28, 2021
American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell LymphomaPashna N Munshi, Mehdi Hamadani, Ambuj Kumar, et al.
Cancer|October 1, 2019
Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failureEmily C Ayers, Shaoying Li, L Jeffrey Medeiros, et al.
Blood Advances|August 5, 2025
Treatment and outcomes of progression of disease post-CAR T-cell therapy in mantle cell lymphoma: a multicenter analysisZachary D Epstein-Peterson, Anath Christopher Lionel, Ashlee Joseph, et al.
Blood Advances|March 12, 2021
Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphomaReid W Merryman, Robert A Redd, Taiga Nishihori, et al.
Blood Advances|October 24, 2023
Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphomaJames N Gerson, Elizabeth Handorf, Diego Villa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 8, 2019
Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab EraJames N Gerson, Elizabeth Handorf, Diego Villa, et al.
Blood Advances|February 24, 2026
Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphomaYucai Wang, Melissa C Larson, Steven R Hwang, et al.
Blood Advances|December 11, 2025
Benefit of Rituximab Maintenance After First-line Bendamustine-Rituximab in Patients with Mantle Cell LymphomaYucai Wang, Melissa C Larson, Steven R Hwang, et al.
Blood Cancer Journal|April 25, 2026
Mantle cell lymphoma outcomes following sequential first-line bendamustine-rituximab and second-line Bruton's tyrosine kinase inhibitor therapyYucai Wang, Melissa C Larson, Steven R Hwang, et al.
Pageof 5